Search research articles
Contact Us
Filters
Showing results (31-40 of 108) with videos related to
Page
of 11
Sort By:
Blood
|
January 15, 1992
A2 domain of human recombinant-derived factor VIII is required for procoagulant activity but not for thrombin cleavage
D D Pittman, M Millenson, K Marquette, et al.
Cognition & Emotion
|
October 15, 2013
When do self-discrepancies predict negative emotions? Exploring formal operational thought and abstract reasoning skills as moderators
Erin N Stevens, Nicole J Holmberg, M Christine Lovejoy, et al.
Journal of Clinical Sleep Medicine : JCSM : Official Publication of the American Academy of Sleep Medicine
|
September 8, 2011
A possible method to predict response to non-pharmacological insomnia therapy
Lisa M Campana, Gari D Clifford, John Trinder, et al.
International Journal of Radiation Oncology, Biology, Physics
|
September 1, 1987
Postgraduate training in radiation oncology in the United States, 1986
J D Cox, D F Flynn, D D Pittman, et al.
Biochemistry
|
June 7, 1994
Posttranslational sulfation of factor V is required for efficient thrombin cleavage and activation and for full procoagulant activity
D D Pittman, K N Tomkinson, D Michnick, et al.
Sleep
|
February 3, 2005
A novel adaptive wrist actigraphy algorithm for sleep-wake assessment in sleep apnea patients
Jan Hedner, Giora Pillar, Stephen D Pittman, et al.
The Journal of Biological Chemistry
|
November 15, 1991
The role of von Willebrand factor multimers and propeptide cleavage in binding and stabilization of factor VIII
R J Wise, A J Dorner, M Krane, et al.
Journal of Applied Physiology (Bethesda, Md. : 1985)
|
March 27, 2010
Phase-rectified signal averaging as a sensitive index of autonomic changes with aging
L M Campana, R L Owens, G D Clifford, et al.
Journal of Thrombosis and Haemostasis : JTH
|
March 16, 2017
Phase 1 dose-escalating study to evaluate the safety, pharmacokinetics, and pharmacodynamics of a recombinant factor Xa variant (FXa<sup>I16L</sup> )
D Parsons-Rich, F Hua, G Li, et al.
Research and Practice in Thrombosis and Haemostasis
|
November 17, 2025
Marstacimab, an antitissue factor pathway inhibitor, combined with bypassing agents: effects on thrombin generation and in hemostatically normal rats
Marjorie A Peraza, Swapnil Rakhe, Susan Hurst, et al.
Page
of 11
Search research articles
Search
Showing results (31-40 of 108) with videos related to
Sort By:
Page
of 11
Blood
|
January 15, 1992
A2 domain of human recombinant-derived factor VIII is required for procoagulant activity but not for thrombin cleavage
D D Pittman, M Millenson, K Marquette, et al.
Cognition & Emotion
|
October 15, 2013
When do self-discrepancies predict negative emotions? Exploring formal operational thought and abstract reasoning skills as moderators
Erin N Stevens, Nicole J Holmberg, M Christine Lovejoy, et al.
Journal of Clinical Sleep Medicine : JCSM : Official Publication of the American Academy of Sleep Medicine
|
September 8, 2011
A possible method to predict response to non-pharmacological insomnia therapy
Lisa M Campana, Gari D Clifford, John Trinder, et al.
International Journal of Radiation Oncology, Biology, Physics
|
September 1, 1987
Postgraduate training in radiation oncology in the United States, 1986
J D Cox, D F Flynn, D D Pittman, et al.
Biochemistry
|
June 7, 1994
Posttranslational sulfation of factor V is required for efficient thrombin cleavage and activation and for full procoagulant activity
D D Pittman, K N Tomkinson, D Michnick, et al.
Sleep
|
February 3, 2005
A novel adaptive wrist actigraphy algorithm for sleep-wake assessment in sleep apnea patients
Jan Hedner, Giora Pillar, Stephen D Pittman, et al.
The Journal of Biological Chemistry
|
November 15, 1991
The role of von Willebrand factor multimers and propeptide cleavage in binding and stabilization of factor VIII
R J Wise, A J Dorner, M Krane, et al.
Journal of Applied Physiology (Bethesda, Md. : 1985)
|
March 27, 2010
Phase-rectified signal averaging as a sensitive index of autonomic changes with aging
L M Campana, R L Owens, G D Clifford, et al.
Journal of Thrombosis and Haemostasis : JTH
|
March 16, 2017
Phase 1 dose-escalating study to evaluate the safety, pharmacokinetics, and pharmacodynamics of a recombinant factor Xa variant (FXa<sup>I16L</sup> )
D Parsons-Rich, F Hua, G Li, et al.
Research and Practice in Thrombosis and Haemostasis
|
November 17, 2025
Marstacimab, an antitissue factor pathway inhibitor, combined with bypassing agents: effects on thrombin generation and in hemostatically normal rats
Marjorie A Peraza, Swapnil Rakhe, Susan Hurst, et al.
Page
of 11